Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Co-secretion of growth hormone and prolactin defines a high-risk acromegaly phenotype.

Pituitary - 18 Jun 2026

Lee Won Kyu, Oh Hyeong-Cheol, Shim Jin-Kyung, Oh Hyeyeon, Won So Young, Choi Seonah, Hwang Yoon-A, Moon Ju Hyung, Ku Cheol Ryong, Lee Eun Jig, Kim Sun Ho, Kim Eui Hyun

Abstract excerpt

BACKGROUND: Data on GH and prolactin (PRL) co-secreting pituitary neuroendocrine tumors (GH/PRL-PitNETs), a subtype of acromegaly, remain limited. In particular, comparative analyses of clinical outcomes, including remission rates, between GH/PRL-PitNETs and GH-secreting pituitary neuroendocrine tumors (GH-PitNETs) are scarce. OBJECTIVE: This study aimed to characterize and compare the clinical course and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acromegaly
Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Growth Hormone

Share to Human Growth Hormone

Share to Neuroendocrine Tumors

Share to Phenotype

Share to Pituitary Neoplasms

Share to Prolactin

Source

Identifiers

PMID: 42315804
DOI: 10.1007/s11102-026-01713-6

Genes

PRL

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Co-secretion of growth hormone and prolactin defines a high-risk acromegaly phenotype.PMID 42315804Read ↗

Co-secretion of growth hormone and prolactin defines a high-risk acromegaly phenotypeSemantic proximity Read ↗

Transcriptomic Classification of Pituitary Neuroendocrine Tumors Causing AcromegalySemantic proximity Read ↗

Transcriptomic classification of pituitary neuroendocrine tumors causing acromegalySemantic proximity Read ↗

Clinical characteristics associated with somatic GNAS mutations in acromegaly: a systematic review and institutional experience.Semantic proximity Read ↗

Pituitary acromegaly: not one diseaseSemantic proximity Read ↗

Standards of Care for Medical Management of Acromegaly in Pituitary Tumor Centers of Excellence (PTCOE)Semantic proximity Read ↗

Growth hormone-producing pituitary adenomas in childhood and young adulthood: clinical features and outcomes.Semantic proximity Read ↗

Proteogenomic landscape and clinical characterization of GH-producing pituitary adenomas/somatotroph pituitary neuroendocrine tumorsSemantic proximity Read ↗

Transcriptomic perspective on acromegaly- related PIT-1/SF-1 positive pituitary tumorsSemantic proximity Read ↗

Subsequent Primary Malignancies in Patients with Initial Diagnosis of Pituitary Adenoma (Pit-NET): a Surveillance, Epidemiology, and End Results (SEER) Data AnalysisSemantic proximity Read ↗

Consensus on acromegaly complications: an updateSemantic proximity Read ↗

Clinical integration and application of the 2022 WHO pituitary tumor classificationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.